Leaders are sticking their heads into the sand of reality on Omicron. Unless they take needed steps, the results may be catastrophic for their companies.
Omicron is 4.2 times more infectious than Delta, according to a recent study. That aligns with other estimates of 3-6 times greater infectivity.
33% protection from infection: that’s the effectiveness of the Pfizer two-shot vaccine against Omicron. That means Omicron is much more capable of escaping vaccines and natural immunity. Similarly worrisome results emerge from studies of Moderna and J&J.
A Pfizer booster vaccine does raise protection to about 75%. Still, surveys show that Omicron has had very little impact on the willingness of Americans to get a booster, or even get a first vaccine dose.
